---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000056"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:41:42.261292+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront

## Summary
- Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.
- Milestone payments tied to development/commercialization and net sales levels; single-digit royalties on worldwide net sales.
- Halozyme named exclusive supplier of API for PH20 product for clinical and commercial supplies.
- Agreement covers development of a subcutaneous formulation of ACU193.

## SEC filing metadata
- accession: 0001576885-23-000056
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/0001576885-23-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/abos-20231105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000056
- JSON: https://secwatch.observer/filing/0001576885-23-000056.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000056.txt

## Key facts
- Material Agreements
  Acumen Pharmaceuticals, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at seven figure upfront payment (effective 2023-11-05).
  - Action: entry
  - Agreement: license
  - Counterparty: Halozyme, Inc.
  - Value: seven figure upfront payment
  - Effective: 2023-11-05
  source text: On November 5, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Non-exclusive Collaboration and License Agreement (the “ Agreement ”) with Halozyme, Inc. (“ Halozyme ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000056/0001576885-23-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.